Reduced susceptibility to cholesterol gallstone formation in mice that do not produce apolipoprotein B48 in the intestine
- PMID: 16175613
- DOI: 10.1002/hep.20867
Reduced susceptibility to cholesterol gallstone formation in mice that do not produce apolipoprotein B48 in the intestine
Abstract
It has been found that polymorphisms in the apolipoprotein (APO)-B gene are associated with cholesterol gallstones in humans. We hypothesized that APO-B plays a major regulatory role in the response of biliary cholesterol secretion to high dietary cholesterol and contributes to cholesterol gallstone formation. In the present study, we investigated whether lack of expression of intestinal Apob48 or Apob100 reduces susceptibility to cholesterol gallstones by decreasing intestinal absorption and biliary secretion of cholesterol in male mice homozygous for an "APO-B48 only" allele (Apob(48/48)), an "APO-B100 only" allele (Apob(100/100)), or a wild-type APO-B allele (Apob+/+) before and during an 8-week lithogenic diet. We found that cholesterol absorption was significantly decreased as a result of the APO-B48 deficiency in Apob(100/100) mice compared with wild-type and Apob(48/48) mice, regardless of whether chow or the lithogenic diet was administered. Consequently, hepatic cholesterol synthesis was significantly increased in Apob(100/100) mice compared with wild-type and Apob(48/48) mice. On chow, the APO-B100 deficiency in Apob(48/48) mice with reduced plasma levels of LDL/VLDL--but not HDL cholesterol--induced relative hyposecretion of biliary bile salts and phospholipids accompanying normal biliary cholesterol secretion. Compared with Apob(48/48) and wild-type mice, lithogenic diet-fed Apob(100/100) mice displayed significantly lower secretion rates of biliary cholesterol, but not phospholipid or bile salts, which results in significant decreases in prevalence rates, numbers, and sizes of gallstones. In conclusion, absence of expression of intestinal Apob48, but not Apob100, reduces biliary cholesterol secretion and cholelithogenesis, possibly by decreasing intestinal absorption and hepatic bioavailability.
Similar articles
-
Lipoprotein clearance mechanisms in LDL receptor-deficient "Apo-B48-only" and "Apo-B100-only" mice.J Clin Invest. 1998 Oct 15;102(8):1559-68. doi: 10.1172/JCI4164. J Clin Invest. 1998. PMID: 9788969 Free PMC article.
-
Studies on the expression of genes encoding apolipoproteins B100 and B48 and the low density lipoprotein receptor in nonhuman primates. Comparison of dietary fat and cholesterol.J Biol Chem. 1989 May 25;264(15):9039-45. J Biol Chem. 1989. PMID: 2722816
-
Endurance exercise training reduces gallstone development in mice.J Appl Physiol (1985). 2008 Mar;104(3):761-5. doi: 10.1152/japplphysiol.01292.2007. Epub 2008 Jan 10. J Appl Physiol (1985). 2008. PMID: 18187606
-
Hepatic cholesterol transport from plasma into bile: implications for gallstone disease.Curr Opin Lipidol. 2004 Jun;15(3):279-86. doi: 10.1097/00041433-200406000-00007. Curr Opin Lipidol. 2004. PMID: 15166783 Review.
-
Lipoprotein size and atherosclerosis susceptibility in Apoe(-/-) and Ldlr(-/-) mice.Arterioscler Thromb Vasc Biol. 2001 Oct;21(10):1567-70. doi: 10.1161/hq1001.097780. Arterioscler Thromb Vasc Biol. 2001. PMID: 11597927 Review.
Cited by
-
Role of Baicalin and Liver X Receptor Alpha in the Formation of Cholesterol Gallstones in Mice.Gastroenterol Res Pract. 2020 Apr 21;2020:1343969. doi: 10.1155/2020/1343969. eCollection 2020. Gastroenterol Res Pract. 2020. PMID: 32382260 Free PMC article.
-
Prevention of gallbladder hypomotility via FATP2 inhibition protects from lithogenic diet-induced cholelithiasis.Am J Physiol Gastrointest Liver Physiol. 2016 May 15;310(10):G855-64. doi: 10.1152/ajpgi.00316.2015. Epub 2016 Mar 31. Am J Physiol Gastrointest Liver Physiol. 2016. PMID: 27033116 Free PMC article.
-
Therapy of gallstone disease: What it was, what it is, what it will be.World J Gastrointest Pharmacol Ther. 2012 Apr 6;3(2):7-20. doi: 10.4292/wjgpt.v3.i2.7. World J Gastrointest Pharmacol Ther. 2012. PMID: 22577615 Free PMC article.
-
Ezetimibe: its novel effects on the prevention and the treatment of cholesterol gallstones and nonalcoholic Fatty liver disease.J Lipids. 2012;2012:302847. doi: 10.1155/2012/302847. Epub 2011 Nov 3. J Lipids. 2012. PMID: 22132342 Free PMC article.
-
Effect of ezetimibe on the prevention and dissolution of cholesterol gallstones.Gastroenterology. 2008 Jun;134(7):2101-10. doi: 10.1053/j.gastro.2008.03.011. Epub 2008 Mar 10. Gastroenterology. 2008. PMID: 18442485 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous